Specifically, we determined whether our NP vaccines formulated with the clinically-relevant melanoma peptide MART-127-35 could induce potent CTL capable of recognizing and killing peptide-pulsed target cells and melanoma tumor cells in vitro. The gene discussed is SEPTIN4; the disease is melanoma.